143 related articles for article (PubMed ID: 33215781)
1. Provider-related barriers and enablers to the provision of hepatitis C treatment by general practitioners in Scotland: A behaviour change analysis.
Whiteley D; Speakman E; Elliott L; Davidson K; Hamilton E; Jarvis H; Quinn M; Flowers P
J Viral Hepat; 2021 Mar; 28(3):528-537. PubMed ID: 33215781
[TBL] [Abstract][Full Text] [Related]
2. Enablers and barriers for the provision of community-based HCV treatment: A case study of a real-world practice.
Pourmarzi D; Smirnov A; Hall L; Thompson H; FitzGerald G; Rahman T
J Viral Hepat; 2020 May; 27(5):484-496. PubMed ID: 31958355
[TBL] [Abstract][Full Text] [Related]
3. Prescribing direct-acting antivirals to treat hepatitis C virus in a general practice setting in Australia: 'so why not do it'?
Heard E; Massi L; Smirnov A; Selvey LA
Intern Med J; 2020 Sep; 50(9):1053-1058. PubMed ID: 31589351
[TBL] [Abstract][Full Text] [Related]
4. Personal, provider and system level barriers and enablers for hepatitis C treatment in the era of direct-acting antivirals: Experiences of patients who inject drugs accessing treatment in general practice settings in Australia.
Heard E; Smirnov A; Massi L; Selvey LA
J Subst Abuse Treat; 2021 Aug; 127():108460. PubMed ID: 34134878
[TBL] [Abstract][Full Text] [Related]
5. Patient and healthcare provider experiences of hepatitis C treatment with direct-acting antivirals in Rwanda: a qualitative exploration of barriers and facilitators.
Serumondo J; Penkunas MJ; Niyikora J; Ngwije A; Kiromera A; Musabeyezu E; Umutesi J; Umuraza S; Musengimana G; Nsanzimana S
BMC Public Health; 2020 Jun; 20(1):946. PubMed ID: 32546216
[TBL] [Abstract][Full Text] [Related]
6. Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists-The practitioner experience.
Marshall AD; Grebely J; Dore GJ; Treloar C
Drug Alcohol Depend; 2020 Jan; 206():107705. PubMed ID: 31718924
[TBL] [Abstract][Full Text] [Related]
7. How can general practitioners support people who inject drugs to engage with direct-acting antiviral treatment for hepatitis C? A qualitative study.
Heard E; Smirnov A; Massi L; Selvey LA
Aust J Gen Pract; 2021 Oct; 50(10):716-721. PubMed ID: 34590083
[TBL] [Abstract][Full Text] [Related]
8. Aiming for elimination: Outcomes of a consultation pathway supporting regional general practitioners to prescribe direct-acting antiviral therapy for hepatitis C.
Wade AJ; McCormack A; Roder C; McDonald K; Davies M; Scott N; Wardrop M; Athan E; Hellard ME
J Viral Hepat; 2018 Sep; 25(9):1089-1098. PubMed ID: 29660212
[TBL] [Abstract][Full Text] [Related]
9. 'Sussing that doctor out.' Experiences and perspectives of people affected by hepatitis C regarding engagement with private general practitioners in South Australia: a qualitative study.
Scarborough J; Miller ER; Aylward P; Eliott J
BMC Fam Pract; 2017 Nov; 18(1):97. PubMed ID: 29187145
[TBL] [Abstract][Full Text] [Related]
10. "Everybody living with a chronic disease is entitled to be cured": Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs.
Goodyear T; Ti L; Carrieri P; Small W; Knight R
Int J Drug Policy; 2020 Jul; 81():102766. PubMed ID: 32416525
[TBL] [Abstract][Full Text] [Related]
11. General practitioners' perceptions of the provision of direct-acting antivirals for hepatitis C within Australian private general practice: an exploratory qualitative study.
Scarborough J; Aylward P; Miller ER
Aust J Prim Health; 2023 Dec; 29(6):661-669. PubMed ID: 37271572
[TBL] [Abstract][Full Text] [Related]
12. Framework for community-based models for treating hepatitis C virus.
Pourmarzi D; Hall L; Smirnov A; Hepworth J; Rahman T; FitzGerald G
Aust Health Rev; 2020 Jun; 44(3):459-469. PubMed ID: 31671288
[TBL] [Abstract][Full Text] [Related]
13. Treatment access is only the first step to hepatitis C elimination: experience of universal anti-viral treatment access in Australia.
Doyle JS; Scott N; Sacks-Davis R; Pedrana AE; Thompson AJ; Hellard ME;
Aliment Pharmacol Ther; 2019 May; 49(9):1223-1229. PubMed ID: 30908706
[TBL] [Abstract][Full Text] [Related]
14. A survey of hepatitis C management by Victorian GPs after PBS-listing of direct-acting antiviral therapy.
Wade A; Draper B; Doyle J; Allard N; Grinzi P; Thompson A; Hellard M
Aust Fam Physician; 2017; 46(4):235-240. PubMed ID: 28376580
[TBL] [Abstract][Full Text] [Related]
15. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of treatment access and scope of a multistate hepatitis C virus Extension for Community Healthcare Outcomes telehealth service in the US Indian Health System, 2017-2021.
Wirth AN; Cushman NA; Reilley BA; Leston JD; Mera JR; Levander XA; Stephens DJ
J Rural Health; 2023 Mar; 39(2):358-366. PubMed ID: 36526593
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study.
Bajis S; Grebely J; Hajarizadeh B; Applegate T; Marshall AD; Ellen Harrod M; Byrne J; Bath N; Read P; Edwards M; Gorton C; Hayllar J; Cock V; Peterson S; Thomson C; Weltman M; Jefferies M; Wood W; Haber P; Ezard N; Martinello M; Maher L; Dore GJ;
J Viral Hepat; 2020 Mar; 27(3):281-293. PubMed ID: 31698545
[TBL] [Abstract][Full Text] [Related]
18.
Byrne C; Radley A; Inglis SK; Beer LJZ; Palmer N; Pham MD; Healy B; Doyle JS; Donnan P; Dillon JF
BMJ Open; 2020 Aug; 10(8):e036501. PubMed ID: 32868356
[TBL] [Abstract][Full Text] [Related]
19. Estimated uptake of hepatitis C direct-acting antiviral treatment among individuals with HIV co-infection in Australia: a retrospective cohort study.
Iranpour N; Dore GJ; Martinello M; Matthews GV; Grebely J; Hajarizadeh B
Sex Health; 2020 Jun; 17(3):223-230. PubMed ID: 32223841
[TBL] [Abstract][Full Text] [Related]
20. Factors affecting hepatitis C treatment intentions among Aboriginal people in Western Australia: a mixed-methods study.
Rashidi A; Higgs P; Carruthers S
Aust Health Rev; 2020 Sep; 44(5):755-762. PubMed ID: 32854816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
